New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors

被引：51

作者：

Gema Bonilla-Hernan, M. ^{[1
]}

Eugenia Miranda-Carus, M. ^{[1
]}

Martin-Mola, Emilio ^{[1
]}

机构：

[1] Univ Autonoma Madrid, Hosp Univ La Paz, Dept Rheumatol, Madrid 28046, Spain

来源：

RHEUMATOLOGY | 2011年 / 50卷 / 09期

关键词：

Rheumatoid arthritis; Treatment; Small molecule; Signalling; kinases; fostamatinib; tofacitinib; ACTIVATED PROTEIN-KINASE; COLLAGEN-INDUCED ARTHRITIS; N-TERMINAL KINASE; DOUBLE-BLIND; TYROSINE KINASE; P38; MAPK; METHOTREXATE; EFFICACY; SAFETY; MULTICENTER;

D O I：

10.1093/rheumatology/ker192

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Orally available small molecule compounds have recently been developed for the treatment of RA, and inhibitors of signalling cascades, specifically inhibitors of kinases, have reached advanced stages of clinical development. The p38 mitogen-activated protein kinase blockers have shown poor clinical response despite encouraging preclinical data. In contrast, inhibitors of the non-receptor tyrosine kinases, spleen tyrosine kinase and janus kinase 3, have demonstrated a significant clinical efficacy together with an acceptable safety profile. We herein present a review on published preclinical and clinical data on these new drugs.

引用

页码：1542 / 1550

页数：9

共 53 条

[1]

A Rac1 inhibitory peptide suppresses antibody production and paw swelling in the murine collagen-induced arthritis model of rheumatoid arthritis [J].

Abreu, Joana R. F. ;

Dontje, Wendy ;

Krausz, Sarah ;

de Launay, Daphne ;

van Hennik, Paula B. ;

van Stalborch, Anne-Marieke ;

ten Klooster, Jean-Paul ;

Sanders, Marjolein E. ;

Reedquist, Kris A. ;

Vervoordeldonk, Margriet J. ;

Hordijk, Peter L. ;

Tak, Paul P. .

ARTHRITIS RESEARCH & THERAPY, 2010, 12 (01)

[2]

Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy [J].

Alten, R. E. ;

Zerbini, C. ;

Jeka, S. ;

Irazoque, F. ;

Khatib, F. ;

Emery, P. ;

Bertasso, A. ;

Rabbia, M. ;

Caulfield, J. P. .

ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (02) :364-367

[3]

Tasocitinib [J].

不详 .

Drugs in R & D, 2010, 10 (4) :271-284

[4]

R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation [J].

Braselmann, Sylvia ;

Taylor, Vanessa ;

Zhao, Haoran ;

Wang, Su ;

Sylvain, Catherine ;

Baluom, Muhammad ;

Qu, Kunbin ;

Herlaar, Ellen ;

Lau, Angela ;

Young, Chi ;

Wong, Brian R. ;

Lovell, Scott ;

Sun, Thomas ;

Park, Gary ;

Argade, Ankush ;

Jurcevic, Stipo ;

Pine, Polly ;

Singh, Rajinder ;

Grossbard, Elliott B. ;

Payan, Donald G. ;

Masuda, Esteban S. .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 319 (03) :998-1008

[5]

The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment [J].

Breedveld, FC ;

Weisman, MH ;

Kavanaugh, AF ;

Cohen, SB ;

Pavelka, K ;

van Vollenhoven, R ;

Sharp, J ;

Perez, JL ;

Spencer-Green, GT .

ARTHRITIS AND RHEUMATISM, 2006, 54 (01) :26-37

[6]

A novel spleen tyrosine kinase inhibitor blocks c-jun N-terminal kinase-mediated gene expression in synoviocytes [J].

Cha, HS ;

Boyle, DL ;

Inoue, T ;

Schoot, R ;

Tak, PP ;

Pine, P ;

Firestein, GS .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 317 (02) :571-578

[7]

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks [J].

Cohen, Stanley B. ;

Emery, Paul ;

Greenwald, Maria W. ;

Dougados, Maxime ;

Furie, Richard A. ;

Genovese, Mark C. ;

Keystone, Edward C. ;

Loveless, James E. ;

Burmester, Gerd-Ruediger ;

Cravets, Matthew W. ;

Hessey, Eva W. ;

Shaw, Timothy ;

Totoritis, Mark C. .

ARTHRITIS AND RHEUMATISM, 2006, 54 (09) :2793-2806

[8]

Evaluation of the Efficacy and Safety of Pamapimod, a p38 MAP Kinase Inhibitor, in a Double-Blind, Methotrexate-Controlled Study of Patients With Active Rheumatoid Arthritis [J].

Cohen, Stanley B. ;

Cheng, Tien-Tsai ;

Chindalore, Vishala ;

Damjanov, Nemanja ;

Burgos-Vargas, Ruben ;

DeLora, Patricia ;

Zimany, Kathleen ;

Travers, Helen ;

Caulfield, John P. .

ARTHRITIS AND RHEUMATISM, 2009, 60 (02) :335-344

[9]

Primary B Cell Immunodeficiencies: Comparisons and Contrasts [J].

Conley, Mary Ellen ;

Dobbs, A. Kerry ;

Farmer, Dana M. ;

Kilic, Sebnem ;

Paris, Kenneth ;

Grigoriadou, Sofia ;

Coustan-Smith, Elaine ;

Howard, Vanessa ;

Campana, Dario .

ANNUAL REVIEW OF IMMUNOLOGY, 2009, 27 :199-227

[10]

CONNELL CA, 2010, ARTHRITS RHEUM S10, V62, pS473

← 1 2 3 4 5 6 →